To evade cytotoxic T lymphocytes (CTLs), human immunodeficiency virus (HIV) encodes a protein called Nef that inhibits the surface expression of the major histocompatibility complex class I molecules (MHC-I) that are most important for CTL recognition. The exact mechanism Nef uses to disrupt MHC-I cell surface expression is unclear. Nef has been shown to bind the same amino acids in the MHC-I cytoplasmic tail that are required for reduction of MHC-I cell surface expression (31) . Nef binding may disrupt MHC-I trafficking by altering transport signals in the MHC-I cytoplasmic tail, by providing new transport signals within Nef, or by promoting the association of MHC-I with a cellular protein.
In addition to affecting MHC-I cell surface expression, Nef accelerates the endocytosis of CD4 (9, 11, 26, 30) through its dileucine motif (4, 8, 10, 12, 19, 20, 23, 27) . However, the mechanism used by Nef to affect MHC-I cell surface expression appears to be different. The dileucine motif in Nef that is needed for the acceleration of CD4 endocytosis is dispensable for the disruption of MHC-I trafficking. In addition, regions of Nef that are needed to reduce MHC-I cell surface expression (N-terminal alpha helix, polyproline, and acidic domains) are dispensable for CD4 downmodulation (1, 6, 12, 21, 32) .
Multiple studies have identified a subset of Nef domains that are required for its effects on MHC-I (1, 6, 13, 21, 32) . These studies have utilized a variety of cell types and expression systems to characterize each mutant. Therefore, to compare the relative importance of each domain, we first established an adenoviral expression system that would provide Nef expression levels in T cells similar to that found during HIV infection. For these studies, we utilized the HIV molecular clone HXB-EP (5, 7), which has a marker gene, PLAP, inserted into the envelope open reading frame. In this construct, Nef is expressed under its normal regulatory elements (Fig. 1A) . Primary T cells transduced with HXB-EP displayed a decreased cell surface expression of HLA-A2, which was dependent upon Nef expression (Fig. 1B) . Additionally, cells transduced with this HIV molecular clone expressed Nef at levels comparable to unmodified molecular clones derived from primary isolates (Fig. 1C) . Therefore, this molecular clone was used as a control to establish an adenoviral multiplicity of infection (MOI) at which CEM T cells could be efficiently transduced to express Nef at levels similar to that found during HIV infection. To determine this MOI, CEM T cells were transduced with a control or Nef-expressing adenovirus at a range of MOIs, stained for either CD4 or HLA-A2, and analyzed by flow cytometry. As shown in Fig. 1D and E, an MOI of 50:1 (based on 293-cell infectivity) yielded Nef expression levels similar to that of HXB-EP and resulted in dramatic effects on MHC-I cell surface expression.
We then used this adenoviral system to examine Nef mutants that are unable to disrupt MHC-I trafficking ( Fig. 2A) . First, we titrated each mutant Nef adenovirus to achieve expression levels comparable to wild-type Nef (Fig. 2B) . Next, each mutant was tested for its capacity to affect HLA-A2 and CD4 surface expression ( Fig. 2C and D) . In these studies, wild-type Nef reduced HLA-A2 cell surface expression approximately fivefold, while cells expressing Nef mutant V 10 E⌬17-26, M 20 A, P 75/78 A, or D 123 G reduced HLA-A2 expression no more than 1.5-fold. Nef mutants E 62-65 Q and P 72/75 A affected HLA-A2 slightly more than the other mutants (approximately twofold) ( Fig. 2C and D) . A partial effect of mutating the acidic domain and the first polyproline domain of Nef is consistent with prior reports (21, 25, 32) . All of these mutants, except D 123 G, were active at CD4 downmodulation ( Fig. 2C  and D) .
There is evidence that Nef primarily disrupts MHC-I cell surface expression in HIV-infected primary T cells by blocking the transport of newly synthesized MHC-I to the cell surface (16) . To determine which domains of Nef were needed for this activity, we performed biochemical transport assays. CEM T cells were first pulse-labeled with 35 S-labeled amino acids for 15 min. They were then treated with a biotinylation reagent, which labeled proteins that reached the cell surface during a subsequent 1-h chase period. HLA-A2 was immunoprecipitated and either directly analyzed or reprecipitated with avidin beads to isolate the subset of HLA-A2 molecules that had reached the cell surface.
As expected, we found that wild-type Nef reduced the amount of HLA-A2 transported to the cell surface in 1 h by three-to sixfold (from about 30% to 5%) ( Fig. 3A Lysates normalized for total protein levels and transduction rates were separated by SDS-polyacrylamide gel electrophoresis and then analyzed by Western blotting using an antibody against Nef (AG11, 1:1,000; James Hoxie, University of Pennsylvania) (14, 15 Fig. 2D with 3B ). Nef has been reported to increase the endocytosis of MHC-I in some cell lines (2, 13, 17, 18, 24, 28) . However, under the conditions used in our studies, this activity of Nef is much less apparent in CEM T cells (16) and in HIV-infected primary T cells that express Nef under its normal regulatory elements (Fig. 3C) .
In order to affect MHC-I trafficking, Nef binds to specific sequences within the cytoplasmic tail of MHC-I (31). To further define the Nef protein domains required for this step, we tested the ability of wild-type Nef and each Nef mutant to coprecipitate with HLA-A2 in T cells. CEM or CEM-A2 cells were transduced with the indicated adenovirus, as shown in Fig. 2 . The cells were incubated in 25 mM NH 4 Cl for 4 h and cross-linked with 2 mM dimethyl 3Ј,3Ј-dithiobispropionimidate (Pierce). The cells were lysed {phosphate-buffered saline, 0.3% 3-[(3-cholamidopropyl)-dimethylammonio]-1-propanesulfonate [CHAPS], 0.1% sodium dodecyl sulfate [SDS], pH 8, 1 mM phenylmethylsulfonyl fluoride}, and 1% of the lysates that were normalized for total protein were set aside for input controls. The remaining lysate was precleared with protein A/G agarose and then immunoprecipitated for HLA-A2 using antibody BB7.2 that had been cross-linked to protein A/G agarose (Oncogene) with dimethyl pimelimidate (Sigma). After washing (Tris-buffered saline, 0.3% CHAPS, 0.1% SDS), the cross-linking was reversed, and immunoprecipitates were eluted by incubation in 150 mM dithiothreitol at 37°C for 30 min. The samples were then analyzed by Western blotting using an antibody against Nef.
As shown in Fig. 4A and B, we were readily able to detect wild-type Nef specifically coprecipitating with HLA-A2. However, Nef mutants V 10 E⌬17-26, M 20 A, and D 123 G did not coprecipitate with HLA-A2. Assessing the requirement for the polyproline region in MHC-I binding was somewhat more complex, because it appeared more unstable than the other mutants and it was therefore difficult to achieve levels that were equal to that of wild-type Nef. Thus, for these experiments, we utilized two different expression levels of wild-type Nef, one lower than what we typically used in this assay. As shown in Fig. 4B , we found that under conditions in which the expression of wild-type Nef was equal to or less than that of each mutant, wild-type Nef always coimmunoprecipitated with HLA-A2, while Nef mutants E 62-65 Q, P 72/75 A, and P 75/78 A did not. Thus, all of the Nef domains required for reduced MHC-I surface expression were also required for Nef to physically associate with HLA-A2, whereas a domain necessary to affect CD4 but not MHC-I trafficking (L 164/165 A) was not (Fig. 4C) .
Some of the Nef domains that we examined have been reported to interact with cellular factors implicated in MHC-I downmodulation. Thus, it was surprising that all of the Nef mutants defective at reducing MHC-I cell surface expression were also defective at interacting with MHC-I. However, it is important to note that our studies do not distinguish whether each Nef domain is needed because of direct interactions with the HLA-A2 cytoplasmic tail or whether it is needed indirectly. For example, the requirement for a particular protein domain in our system could be secondary to nonspecific effects of protein unfolding. Alternatively, it is also possible that some domains are required to interact with cellular factors that stabilize the Nef-MHC-I complex. Finally, it is possible that some domains affect the intracellular localization of Nef. However, in our studies we observed no dramatic change in Nef intracellular localization that would explain the defects we observed (data not shown).
In summary, using a physiologically relevant cell type (T cells), our results demonstrated that Nef mutants that are defective at affecting MHC-I trafficking also failed to inhibit MHC-I export and were unable to coprecipitate with MHC-I. Thus, these studies emphasize the importance of the Nef-MHC-I interaction with respect to Nef's effects on antigen presentation and CTL immune evasion.
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